Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot® platform
Press Release , 27 September, 2021 Gothenburg, Sweden, 27 Sept 2021 - Oblique Therapeutics today announces that it has reached a key milestone in its aKRAS antibody program and achieved validation of its Abiprot® platformOblique Therapeutics has developed a unique, proprietary methodology Abiprot[®] to identify epitopes on targets that have previously proven difficult to address with antibodies. Using this platform, a few epitopes were identified in KRAS, one of which encompassed the frequently mutated amino acids 12 and 13. Interestingly, this epitope is not well exposed in any of